The South Korea Anxiety Disorder and Depression Market is witnessing steady growth as mental health gains greater recognition as a public health priority. Rapid urbanization, work-related stress, academic pressure, and social isolation have contributed to a rising prevalence of anxiety and depressive disorders across age groups. Valued at USD 148.07 Million in 2025, the market is expected to grow at a CAGR of 4.20%, reaching USD 223.43 Million by 2035, driven by improved diagnosis rates and increasing adoption of antidepressant therapies.

Market Overview and Key Drivers

South Korea’s mental healthcare landscape has evolved significantly over the past decade. Government-led awareness campaigns, policy reforms, and expanded insurance coverage for psychiatric treatment are improving access to care. The growing acceptance of mental health treatment, combined with an aging population vulnerable to depression, continues to fuel demand for pharmacological and therapeutic interventions.

Emerging Trends in the Market

A key trend shaping the market is the shift toward newer-generation antidepressants with improved safety and efficacy profiles. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) remain widely prescribed. Additionally, digital mental health solutions, including telepsychiatry, mobile therapy apps, and AI-enabled screening tools, are gaining traction—particularly among younger, tech-savvy patients. Personalized treatment approaches and integrated care models are also emerging as important trends.

Growth Opportunities

Significant growth opportunities exist in early diagnosis and preventive mental healthcare, especially through workplace wellness programs and school-based mental health initiatives. Expansion of outpatient psychiatric services and increasing demand for long-term depression management therapies are expected to drive market expansion. Furthermore, collaborations between pharmaceutical companies and digital health providers could unlock new treatment delivery models.

Challenges and Market Restraints

Despite progress, the market faces challenges such as social stigma surrounding mental illness, which can delay diagnosis and treatment. Limited availability of mental health professionals, particularly outside urban centers, and concerns over long-term antidepressant use also pose constraints. Regulatory approval timelines for novel therapies may further slow innovation.

Download your free sample report with an in-depth table of contents now.

Competitive Landscape

The market is moderately competitive, with multinational and domestic pharmaceutical companies focusing on portfolio expansion and localized strategies. Key players include Pfizer Inc. (Pfizer Korea Co., Ltd.), Eli Lilly and Company, H. Lundbeck A/S (Lundbeck Korea Co., Ltd.), Korea Otsuka Pharmaceutical Co., Ltd., and Janssen Korea Co., Ltd. (Johnson & Johnson Services, Inc.), along with other regional participants. Strategic partnerships, clinical trials, and patient education initiatives are central to competitive positioning.